comprehensive -WSS

comprehensive

author：hotspot 2025-09-03 03:28:11 - browse：29217

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Crowdfunding for medical bills sidesteps core problem, author says

WSS

Empower primary care with adequate payments and technology

Winning ticket for $1 billion Powerball jackpot sold in California

The creative science of coining drug names

PBM executives asked to testify by House panel

Mass General totes up its waste in a move to tackle climate change

As health system earnings go up, health insurance stocks go down

Wikipedia

comprehensive

hotspot

Psychedelics group wrestles with new pharma identity

I learned firsthand about improving diversity in clinical trials

As demand for Covid shots wanes, Moderna seeks its next success

Study identifies new proteins linked to dementia risk 25 years later

FDA approval of Sarepta Duchenne genetic therapy gives me hope

EF3 tornado rips through North Carolina amid extreme weather nationwide

Novavax promises a turnaround & Lilly roils the obesity market

AltruBio raises $225 million to develop ulcerative colitis drug

How one medical school became remarkably diverse

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

knowledge

EF3 tornado rips through North Carolina amid extreme weather nationwide

Vir antibody drug aimed at influenza A fails in clinical trial

Novel spinal cord stimulator treats paralysis without surgery

HHS's proposed rule does nothing to address the climate crisis

Primary care doctor shortage won't be solved by free med school tuition

Stanford president's case begs question: Who takes blame?

Wikipedia

leisure time

hotspot

focus